Journal
ATHEROSCLEROSIS
Volume 226, Issue 1, Pages 3-8Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2012.08.018
Keywords
Angiotensin 1-7; Angiotensin II; Angiotensin converting enzyme 2; Atherosclerosis; Renin-angiotensin system
Funding
- National Health and Medical Research Council [540404/1021416]
- BUPA Foundation
- National Health and Medical Research Council, Australia [1019921]
- Queensland Government
Ask authors/readers for more resources
Angiotensin converting enzyme 2 (ACE2) is a homolog of angiotensin converting enzyme (ACE) which generates angiotensin II from angiotensin I. ACE, its product angiotensin II and the downstream angiotensin type I receptor are important components of the renin-angiotensin system (RAS). Angiotensin II, the most important component of the RAS, promotes the development of atherosclerosis. The identification of ACE2 in 2000 opened a new chapter of research on the regulation of the RAS. ACE2 degrades pro-atherosclerotic angiotensin II and generates anti-atherosclerotic angiotensin 1-7. In this review, we explored the importance of ACE2 in protecting experimental animals from developing atherosclerosis and its involvement in human atherosclerosis. We also examined the published evidence assessing the importance of ACE2 in different cell types relevant to atherosclerosis and putative underlying cellular and molecular mechanisms linking ACE2 with protection from atherosclerosis. ACE2 shifts the balance from angiotensin II to angiotensin 1-7 inhibiting the progression of atherosclerosis in animal models. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available